* Options and stocks columns indicate value realized on exercise of options and on vesting of restricted stocks, respectively. 1. Murphy's employment as senior vice president of sales and services terminated in August 2008. 2. Tebbutt's employment with the company ended on May 31, 2009. 3. Other compensation for Caruso consists of the following: (i) executive relocation expenses totaling $65,000, which total includes temporary living expenses of $28,000, travel between home and office of $33

Total: $569,069

Total: $589,224

Total: $596,120

Total: $631,387

Total: $545,488

Total: $1,026,206

Number of companies 203 Total number of employees >119,000 Average number of employees 602 Median number of employees 113 Total market capitalization $258.5 billion Average market capitalization $1.3 billion Median market capitalization $171.0 million Smallest market capitalization $185,210 (N. American Scientific) Largest market capitalization $61.6 billion (Amgen Inc.) Total shares outstanding 12.5 billion Average shares outstanding 61.1 million Median shares outstanding

Staff Writer Tighter-squeezed, tailor-made executive compensation packages these days grow not only from economic straits but from longstanding pressures that have faced biotech firms and others. But it's worse now. The situation is "much more complicated than just the fact we're in the financial doldrums with everybody wondering, 'When do I get my share, and how things will improve?'" said Paul Dorf, managing director of Compensation Resources Inc., which provides consulting services to

Assistant Managing Editor The economy, which began its monumental slide in the latter half of 2008, left companies across all industries broke and employees jobless. But, while some industries have been particularly hard on their executives (see the banking and automotive industries), the biotech business proves that talented leaders are still in high demand. Though the number of publicly traded biotech firms included in BioWorld's 2010 Executive Compensation Report has dwindled from last year

The data presented in this book were obtained from proxy statements and annual reports of biotechnology companies that were filed with the U.S. Securities and Exchange Commission (SEC) for fiscal year 2008. Important Notes The executives/officers listed for the 203 companies surveyed are the individual who held that title for the majority of the fiscal year reported. Companies disclose compensation only for the five most highly paid executives or, in the case of small companies, for executives

For the 82 legal officers in BioWorld's company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 Stephen G. Juelsgaard GENENTECH INC 514 780 1,294 2 Peter Wirth GENZYME CORP 705 560 1,265 3 Glenn E. Deegan MACROCHEM CORP/DE 850 - 850 4 Paul Mahon UNITED THERAPEUTICS CORP 578 93 672 5 Gregg H. Alton GILEAD SCIENCES INC 416 235 651 6 Marianne Armstrong INTERMUNE INC 318 278 596 7 James H. Davis HUMAN

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options ($k) Stocks ($k) AASTROM BIOSCIENCES Robert J. Bard 217 - 217 11 141 370 - 5 ACCENTIA BIOPHARMA Samuel S. Duffey1. 304 75 379 38 937 1,356 - - ACHILLION PHARMA Gautam Shah2 253 60 313 7 93 415 13 - ACORDA THERAPEUTICS Jane Wasman 270 81 351 6 529 887 - 398 ACUSPHERE Dennis Bucceri 275 - 275 70 27 373 - - ALEXION PHARMA Thomas I

For the 164 research and development executives BioWorld s company survey who received base salary plus bonus* Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 John West ILLUMINA INC 375 4,223 4,598 2 Susan D. Desmond-Hellmann GENENTECH INC 664 1,200 1,864 3 Roger M. Perlmutter AMGEN INC 908 605 1,513 4 Cecil B. Pickett BIOGEN IDEC INC 796 561 1,357 5 Norbert W. Bischofberger GILEAD SCIENCES INC 637 523 1,161 6 George D. Yancopoulos , REGENERON

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options ($k) Stocks ($k) AASTROM BIOSCIENCES Elmar R. Burchardt 187 - 187 69 91 348 - - ACADIA PHARMA Bo-Ragnar Tolf1 304 62 367 63 94 525 - - ACCELRYS Nicholas Austin2 238 98 337 0 198 536 - 5 ACCESS PHARMA David P. Nowotnik 253 - 253 12 - 265 - - ACHILLION PHARMA Milind Deshpande3 264 66 330 8 189 528 - - ACORDA THERAPEUTICS Andrew R

For the 76 business and corporate development executives in BioWorld s company survey who received base salary plus bonus Rank Executive Company Salary ($k) Bonus ($k) Total ($k) 1 George J. Morrow AMGEN INC 961 640 1,601 2 Barry A. Labinger HUMAN GENOME SCIENCES INC 460 205 665 3 Geoffrey M. Nichol MEDAREX INC 400 191 591 4 John A. Keller INCYTE CORP 339 245 584 5 Philip K. Yachmetz SAVIENT PHARMACEUTICALS INC 357 222 579 6 James V. Caruso ALLOS

Company Executive Salary ($k) Bonus ($k) Total Cash ($k) Other ($k) Long-term ($k) Total direct ($k) Options ($k) Stocks ($k) ACADIA PHARMA Roger Mills1 342 85 427 0 164 593 - - ACCELRYS R. William Taylor 240 98 338 0 144 483 - - ACCESS PHARMA Phillip S. Wise 200 - 200 9 - 209 - - ALEXZA PHARMA Anthony G. Tebbut2 304 48 353 159 266 778 - - ALKERMES Michael J. Landine 315 160 475 6 961 1,443 - 85 ALLOS THERAPEUTICS James V. Caruso3 377